Literature DB >> 16640512

Radioiodine therapy in hyperthyroid disease: poorer outcome in patients with high 24 hours radioiodine uptake.

Ulrik Sloth Kristoffersen1, Birger Hesse, Ase Krogh Rasmussen, Andreas Kjaer.   

Abstract

PURPOSE: To evaluate the importance of 24 h radioiodine uptake (24 h RIU) for the outcome of radioiodine treatment of hyperthyroidism.
METHODS: Retrospective analysis of 72 patients who underwent radioiodine treatment for toxic goiter at our outpatient clinic [29 diffuse goiters (DG), 30 toxic multinodular goiters (TMG) and 13 toxic adenomas (TA)]. Thyroid status was determined by TSH, fT3 and fT4 levels, and outcome was rendered successful when hyperthyroidism was absent. Relation between low 24 h RIU (below median) or high 24 h RIU (above or equal to median) and outcome was evaluated.
RESULTS: Of patients with DG and low 24 h RIU, 15% remained hyperthyroid, as opposed to 56% of patients with DG and high 24 h RIU (P<0.05). Of patients with TMG and low 24 h RIU, none remained hyperthyroid, as opposed to 44% of patients with TMG and high 24 h RIU (P<0.01). Of patients with TA and low 24 h RIU, none remained hyperthyroid, as opposed to 43% of patients with TA and high 24 h RIU (NS, P = 0.19).
CONCLUSION: In patients with hyperthyroid disease treated with radioiodine the outcome is poorer for patients with high 24 h RIU compared with low 24 h RIU measured prior to treatment when the radioiodine dose is calculated on the basis of 24 h RIU.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16640512     DOI: 10.1111/j.1475-097X.2006.00666.x

Source DB:  PubMed          Journal:  Clin Physiol Funct Imaging        ISSN: 1475-0961            Impact factor:   2.273


  7 in total

1.  Is There Any Need for Adjusting 131I Activity for the Treatment of High Turnover Graves' Disease Compared to Normal Turnover Patients? Results from a Retrospective Cohort Study Validated by Propensity Score Analysis.

Authors:  Saurabh Arora; Chandrasekhar Bal
Journal:  Nucl Med Mol Imaging       Date:  2021-01-07

2.  Novel Application of Quantitative Single-Photon Emission Computed Tomography/Computed Tomography to Predict Early Response to Methimazole in Graves' Disease.

Authors:  Hyun Joo Kim; Ji-In Bang; Ji-Young Kim; Jae Hoon Moon; Young So; Won Woo Lee
Journal:  Korean J Radiol       Date:  2017-04-03       Impact factor: 3.500

3.  Predictive Value of a Thyroid-Absorbed Dose with a Shorter Effective Half-Life on Efficacy in Graves Disease Patients Receiving Iodine-131 Therapy.

Authors:  Feng Yu; Ruiguo Zhang; Guizhi Zhang; Zhaowei Meng; Xiaohua Liu; Yajing He; Jian Tan; Renfei Wang
Journal:  Med Sci Monit       Date:  2021-01-26

4.  The effect of prior antithyroid drug use on delaying remission in high uptake Graves' disease following radioiodine ablation.

Authors:  Muthiah Subramanian; Manu Kurian Baby; Krishna G Seshadri
Journal:  Endocr Connect       Date:  2016-01-15       Impact factor: 3.335

5.  Efficacy of radioactive iodine treatment of graves' hyperthyroidism using a single calculated 131I dose.

Authors:  Ka Kit Wong; Barry L Shulkin; Milton D Gross; Anca M Avram
Journal:  Clin Diabetes Endocrinol       Date:  2018-11-28

6.  Predictors of euthyreosis in hyperthyroid patients treated with radioiodine 131I-: a retrospective study.

Authors:  Albert Stachura; Tomasz Gryn; Bernadetta Kałuża; Tadeusz Budlewski; Edward Franek
Journal:  BMC Endocr Disord       Date:  2020-06-01       Impact factor: 2.763

7.  Radioiodine Therapy of Graves' Disease and the Uptake Paradox.

Authors:  Sumeet Suresh Malapure; Anirban Mukherjee; Chandrasekar Bal
Journal:  Indian J Nucl Med       Date:  2019-12-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.